Skip to main content
31 Oct 2023

Predicting cancer patient response to PARP inhibitors

By analysing more than 80 clinical trials, researchers at Garvan have identified genetic tests that predict which cancer patients are likely to benefit from PARP inhibitors in combination with chemotherapy.

Read Article
Liz Caldon